Fig. 2

Associations between AZIN1 RNA editing with tumor recurrence and survival outcomes in GC patients. a OS in GC patients in relation to AZIN1 RNA editing (left) and ADAR1 expression levels (right). OS was significantly lower in GC patients with high AZIN1 RNA editing levels or high ADAR1 expression levels compared with those with low levels of either parameter (AZIN1 RNA editing; P = 0.01, ADAR1 expression; P = 0.034, log-rank test). b Kaplan–Meier survival curves for DFS in GC patients in relation to AZIN1 RNA editing (left) and ADAR1 expression levels (right). DFS was significantly lower in GC patients with high AZIN1 RNA editing levels or high ADAR1 expression levels compared with those with low levels of either parameter. c Correlation between ADAR1 expression and AZIN1 editing in gastric cancer patients. (AZIN1 RNA editing; P < 0.0001, ADAR1 expression; P = 0.12, log-rank test). All statistical tests were two-sided